A Phase 1 interventional study of MYK-224 and Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-13.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the effects of both single and multiple dose drug levels of MYK-224 in healthy adult Japanese participants.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MYK-224 · Other: Placebo
Drug: MYK-224 · Other: Placebo
Drug: MYK-224 · Other: Placebo
Drug: MYK-224 · Other: Placebo
Specified dose on specified days
Also known as: BMS-986435
Specified dose on specified days
Maximum observed plasma concentration (Cmax)
Time frame: Up to 72 days
Time of maximum observed concentration (Tmax)
Time frame: Up to 72 days
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])
Time frame: Up to 72 days
Number of participants with adverse events (AEs)
Time frame: Up to 130 days
Number of participants with serious adverse events (SAEs)
Time frame: Up to 130 days
Number of participants with adverse events leading to discontinuation
Time frame: Up to 130 days
Number of participants with vital sign abnormalities
Time frame: Up to 72 days
Number of participants with physical exam abnormalities
Time frame: Up to 72 days
Number of participants with clinical laboratory abnormalities
Time frame: Up to 72 days
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 72 days
Measurement of left ventricular ejection fraction (LVEF)
Time frame: Up to 72 days
Measurement of left ventricular outflow tract velocity time integral (LVOT-VTI)
Time frame: Up to 72 days
Measurement of left ventricular fractional shortening (LVFS)
Time frame: Up to 72 days
Measurement of left ventricular global longitudinal strain (LV GLS)
Time frame: Up to 72 days
Measurement of left ventricle stroke volume (LVSV)
Time frame: Up to 72 days
Measurement of lateral and septal early diastolic mitral annular velocity (e')
Time frame: Up to 72 days
Measurement of early diastolic mitral inflow velocity to early diastolic mitral annular velocity (E/e')
Time frame: Up to 72 days
Measurement of early diastolic mitral inflow velocity to late diastolic mitral inflow velocity ratio (E/A ratio)
Time frame: Up to 72 days
Measurement of left ventricular (LV) mass index
Time frame: Up to 72 days
Measurement of left atrial volume index
Time frame: Up to 72 days
Measurement of interventricular septal thickness
Time frame: Up to 72 days
Measurement of posterior wall thickness
Time frame: Up to 72 days
Measurement of LV end diastolic volume
Time frame: Up to 72 days
Measurement of LV end diastolic volume index
Time frame: Up to 72 days
Measurement of LV end systolic volume
Time frame: Up to 72 days
Measurement of LV end systolic volume index
Time frame: Up to 72 days
Relative bioavailability of test formulation compared to the reference formulation based on Cmax
Time frame: Up to 72 days
Relative bioavailability of test formulation compared to the reference formulation based on AUC(0-T)
Time frame: Up to 72 days
Relative bioavailability of test forumulation compared to the reference formulation based on area under the concentration-time curve from time zero extrapolated to infinite time AUC(INF)
Time frame: Up to 72 days
Ran from Jul 2022 to primary completion in Nov 2022, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delocamten